日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

布立伐尼治疗晚期实体瘤患者的II期随机停药试验

Jones, Robin L; Ratain, Mark J; O'Dwyer, Peter J; Siu, Lillian L; Jassem, Jacek; Medioni, Jacques; DeJonge, Maja; Rudin, Charles; Sawyer, Michael; Khayat, David; Awada, Ahmad; de Vos-Geelen, Judith M P G M; Evans, T R Jeffry; Obel, Jennifer; Brockstein, Bruce; DeGreve, Jacques; Baurain, Jean-Francois; Maki, Robert; D'Adamo, David; Dickson, Mark; Undevia, Samir; Geary, David; Janisch, Linda; Bedard, Philippe L; Abdul Razak, Albiruni R; Kristeleit, Rebecca; Vitfell-Rasmussen, Joanna; Walters, Ian; Kaye, Stan B; Schwartz, Gary

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

口服 AKT 抑制剂 MK-2206 联合卡铂/紫杉醇、多西他赛或厄洛替尼治疗晚期实体瘤患者的 1 期临床试验

Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna; Zernhelt, Adriane M; Sullivan, Daniel M; Cassier, Philippe A; Chen, Eric; Biondo, Andrea; Tetteh, Ernestina; Siu, Lillian L; Patnaik, Amita; Papadopoulos, Kyriakos P; de Bono, Johann S; Tolcher, Anthony W; Minton, Susan